Published in Proc Natl Acad Sci U S A on June 24, 1997
Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol (2009) 1.96
Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol (2000) 1.66
Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) 1.45
Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J Exp Med (2002) 1.38
The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol Immunother (2007) 1.10
ER stress affects processing of MHC class I-associated peptides. BMC Immunol (2009) 1.02
Diversity in MHC class II antigen presentation. Immunology (2002) 1.01
Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation. Mol Cell Biol (2001) 1.01
Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology (2012) 0.97
Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome. Rev Bras Hematol Hemoter (2012) 0.93
On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br J Cancer (2003) 0.92
Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica (2009) 0.90
Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int J Clin Exp Pathol (2010) 0.86
Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients. Mol Cell Proteomics (2012) 0.85
Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol (2008) 0.85
HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome. PLoS One (2013) 0.84
Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. Cancer Immunol Immunother (2010) 0.84
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-gamma in promyelocytic cells. Int Immunol (2008) 0.84
MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer (2000) 0.84
Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects. Exp Mol Med (2011) 0.83
Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells. PLoS One (2012) 0.81
Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunol Immunother (2009) 0.80
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res (2016) 0.80
A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform. Mol Cancer (2010) 0.78
Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells. Br J Cancer (1999) 0.77
Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine. Immunology (2006) 0.77
The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells. Immunology (2009) 0.77
Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells. Cancer Immunol Immunother (2015) 0.77
Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation. Oncoimmunology (2012) 0.75
Prolonged expression of MHC class I - peptide expression in bone marrow derived retrovirus transfected matured dendritic cells by continuous centrifugation in the presence of IL-4. Indian J Med Res (2011) 0.75
A C-terminal signal prevents secretion of luminal ER proteins. Cell (1987) 14.83
Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. Curr Top Microbiol Immunol (1978) 13.40
Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol (1988) 6.51
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
Sequence analysis of peptides bound to MHC class II molecules. Nature (1991) 5.99
The basic science of gene therapy. Science (1993) 5.94
Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell (1993) 4.80
The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol (1993) 4.35
Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature (1991) 4.04
Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science (1994) 3.71
Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. J Exp Med (1986) 2.55
Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med (1994) 2.42
Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol (1996) 2.42
Mice lacking the MHC class II-associated invariant chain. Cell (1993) 2.30
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27
Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression. J Exp Med (1993) 2.27
HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol (1989) 2.11
Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science (1995) 2.01
An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells. J Exp Med (1990) 1.94
Differential expression of Ia and Ia-associated invariant chain in mouse tissues after in vivo treatment with IFN-gamma. J Immunol (1986) 1.82
Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature (1990) 1.77
Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med (1995) 1.77
IA mutant functional antigen-presenting cell lines. J Immunol (1983) 1.76
Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A (1993) 1.72
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res (1994) 1.64
Cell surface expression of class II histocompatibility antigens occurs in the absence of the invariant chain. J Exp Med (1986) 1.61
The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules. J Exp Med (1994) 1.59
Human tumor antigens recognized by T cells. Curr Opin Immunol (1996) 1.54
Antigenic regions defined by monoclonal antibodies correspond to structural domains of avian lysozyme. J Immunol (1984) 1.46
Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med (1995) 1.45
The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity. J Exp Med (1978) 1.43
Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity (1994) 1.39
Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol (1990) 1.39
Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells. Science (1994) 1.33
Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J (1996) 1.28
Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum Gene Ther (1995) 1.13
Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants. Proc Natl Acad Sci U S A (1997) 1.13
Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol (1994) 1.12
Allelic differences affecting invariant chain dependency of MHC class II subunit assembly. Immunity (1995) 1.10
The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes. Int Immunol (1995) 1.07
T cell receptor gene segment usage in a panel of hen-egg white lysozyme specific, I-Ak-restricted T helper hybridomas. J Immunol (1989) 1.07
Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes. J Immunol (1994) 1.06
Antigen presentation of hen egg-white lysozyme but not of ribonuclease A is augmented by the major histocompatibility complex class II-associated invariant chain. Eur J Immunol (1991) 1.02
Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J Immunol (1991) 1.01
Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A (1996) 0.99
The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16. Immunology (1991) 0.97
Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J Immunol (1992) 0.96
Biological implications of HLA-DR expression in tumours. Scand J Immunol (1995) 0.96
Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol (1993) 0.95
Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today (1985) 0.94
Epitopic analysis by anti-I-Ak monoclonal antibodies of I-Ak-restricted presentation of lysozyme peptides. J Immunol (1989) 0.92
Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens (1996) 0.84
New strategies for active immunotherapy with genetically engineered tumor cells. Curr Opin Immunol (1992) 0.84
Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet (1988) 0.82
Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes. J Leukoc Biol (1994) 0.79
Cancer vaccines: a road map for the next decade. Curr Opin Immunol (1996) 0.78
Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host. Cell Immunol (1990) 0.77
The novelty of antigen-processing compartments. J Immunol (1995) 0.77
Double-masked randomized trial comparing alternate combinations of intraoperative anesthesia and postoperative analgesia in abdominal aortic surgery. Anesthesiology (2001) 5.54
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci (2001) 3.50
Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res (1998) 3.00
A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science (1990) 2.83
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology (2007) 2.54
Mouse 4T1 breast tumor model. Curr Protoc Immunol (2001) 2.46
How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene. EMBO J (2000) 2.33
Upstream DNA sequences required for tissue-specific expression of the HLA-DR alpha gene. Proc Natl Acad Sci U S A (1987) 2.00
A kinetic study of drug elimination: the excretion of paracetamol and its metabolites in man. Br J Pharmacol Chemother (1967) 1.99
GTP binding by class II transactivator: role in nuclear import. Science (1999) 1.94
BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat Immunol (2000) 1.76
Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A (1993) 1.72
Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol (2000) 1.66
Kinetic considerations relating to the accrual and elimination of drug metabolites. Br J Pharmacol Chemother (1967) 1.63
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol (1998) 1.63
Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol Cell Biol (2000) 1.62
CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors. EMBO J (1994) 1.53
Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity (1997) 1.51
Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol Cell Biol (1999) 1.50
Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J Exp Med (1995) 1.46
Detailed delineation of an interferon-gamma-responsive element important in human HLA-DRA gene expression in a glioblastoma multiform line. Proc Natl Acad Sci U S A (1988) 1.46
Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med (1995) 1.45
Identification of an interferon-gamma response region 5' of the human histocompatibility leukocyte antigen DR alpha chain gene which is active in human glioblastoma multiforme lines. J Immunol (1987) 1.45
MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem (2000) 1.40
Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity (1994) 1.39
Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8+ T cells in IRF-1-/- mice. Immunity (1996) 1.35
A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity (1999) 1.31
[Comparative study of gastro-intestinal blood loss after antrafenine, aspirin and placebo in healthy volunteers (author's transl)]. Therapie (1981) 1.28
Cyclin-dependent kinase activation and S-phase induction of the cyclin B1 gene are linked through the CCAAT elements. Cell Growth Differ (1997) 1.28
IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol (2000) 1.26
Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein. Immunity (2001) 1.26
Class II box consensus sequences in the HLA-DR alpha gene: transcriptional function and interaction with nuclear proteins. Mol Cell Biol (1989) 1.24
Detection of rare mRNAs via quantitative RT-PCR. Trends Genet (1992) 1.22
Functional analysis of c-Myb protein in T-lymphocytic cell lines shows that it trans-activates the c-myc promoter. Mol Cell Biol (1990) 1.20
Identification of distinct regions of 5' flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. J Immunol (1998) 1.20
CCAAT-binding factor NF-Y and RFX are required for in vivo assembly of a nucleoprotein complex that spans 250 base pairs: the invariant chain promoter as a model. Mol Cell Biol (1997) 1.20
Drug urinary excretion data--some aspects concerning the interpretation. Br J Pharmacol Chemother (1967) 1.18
The transcriptional regulatory protein, YB-1, promotes single-stranded regions in the DRA promoter. J Biol Chem (1995) 1.17
Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains. Mol Cell Biol (2001) 1.16
Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol (2000) 1.16
Treatment of data from drug urinary excretion. Nature (1967) 1.15
In vivo footprint analysis of the HLA-DRA gene promoter: cell-specific interaction at the octamer site and up-regulation of X box binding by interferon gamma. Proc Natl Acad Sci U S A (1992) 1.15
Major histocompatibility complex class II-associated invariant chain gene expression is up-regulated by cooperative interactions of Sp1 and NF-Y. J Biol Chem (1995) 1.13
Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants. Proc Natl Acad Sci U S A (1997) 1.13
Stereospecific alignment of the X and Y elements is required for major histocompatibility complex class II DRA promoter function. Mol Cell Biol (1991) 1.12
Expression and synthesis of murine immune response-associated (Ia) antigens by brain cells. Proc Natl Acad Sci U S A (1981) 1.11
Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain. J Immunol (1999) 1.10
Absence of MHC class II molecules reduces CNS demyelination, microglial/macrophage infiltration, and twitching in murine globoid cell leukodystrophy. Cell (1994) 1.10
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol Immunother (2000) 1.09
Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol (2000) 1.09
Isolation and characterization of a human pro alpha 2(I) collagen gene segment. J Invest Dermatol (1984) 1.08
Affinity-purified CCAAT-box-binding protein (YEBP) functionally regulates expression of a human class II major histocompatibility complex gene and the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A (1991) 1.08
CIITA stimulation of transcription factor binding to major histocompatibility complex class II and associated promoters in vivo. Proc Natl Acad Sci U S A (1998) 1.07
Mechanisms of nuclear import and export that control the subcellular localization of class II transactivator. J Immunol (2001) 1.07
Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection. J Immunol (1993) 1.06
A 36-amino-acid region of CIITA is an effective inhibitor of CBP: novel mechanism of gamma interferon-mediated suppression of collagen alpha(2)(I) and other promoters. Mol Cell Biol (2001) 1.05
X-box-binding proteins positively and negatively regulate transcription of the HLA-DRA gene through interaction with discrete upstream W and V elements. Proc Natl Acad Sci U S A (1990) 1.05
Potential effect of the plasma on drug distribution. Nature (1965) 1.05
Trazodone--a new assay procedure and some pharmacokinetic parameters. Br J Clin Pharmacol (1981) 1.04
Structural constraints within a trimeric transcriptional regulatory region. Constitutive and interferon-gamma-inducible expression of the HLA-DRA gene. J Biol Chem (1992) 1.03
Mechanism of c-myc regulation by c-Myb in different cell lineages. Mol Cell Biol (1993) 1.03
Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol Cell Biol (1997) 1.02
Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem (1998) 1.02
The elimination of salicylic acid in man: serum concentrations and urinary excretion rates. Br J Pharmacol Chemother (1966) 1.02
Function of NF-kappa B/Rel binding sites in the major histocompatibility complex class II invariant chain promoter is dependent on cell-specific binding of different NF-kappa B/Rel subunits. Mol Cell Biol (1994) 1.01
Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines. Mol Cell Biol (2001) 1.01
Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J Immunol (1991) 1.01
The octamer motif is a B-lymphocyte-specific regulatory element of the HLA-DR alpha gene promoter. Proc Natl Acad Sci U S A (1989) 1.01
Allogeneic H-2 antigen expression is insufficient for tumor rejection. Proc Natl Acad Sci U S A (1987) 1.00
Transcriptional regulation of the HLA-DRA gene. Crit Rev Immunol (1991) 1.00
Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis (2000) 0.98
Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J Immunol (1992) 0.96
H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma. J Immunol (1988) 0.95
Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother (1998) 0.95
Usage of primary cells to delineate IFN-gamma-responsive DNA elements in the HLA-DRA promoter and to identify a novel IFN-gamma-enhanced nuclear factor. J Immunol (1992) 0.95
A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes. J Biol Chem (1999) 0.95
Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants. J Immunol (1997) 0.94
Biosynthesis and intracellular targeting of the lysosomal aspartic proteinase cathepsin D. Adv Exp Med Biol (1998) 0.94
Expression of class I histocompatibility antigens on human T-B lymphoblast hybrids. Somat Cell Mol Genet (1984) 0.94
Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol (1989) 0.94
Regulation of inosine-5'-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5' palindromic octamer sequence. J Biol Chem (1997) 0.93
Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. Am J Ophthalmol (2001) 0.93
Recognition of MHC TL gene products by gamma delta T cells. Immunol Rev (1991) 0.92
Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol (1996) 0.92
Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol Rev (1999) 0.90
Embryonal carcinoma cells express Qa and Tla class I genes of the major histocompatibility complex. Proc Natl Acad Sci U S A (1989) 0.90
Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha. J Neuroimmunol (1999) 0.90
Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes. Int J Cancer Suppl (1991) 0.90
Tyrosine phosphorylation of a c-Src-like protein is increased in membranes of CD4- CD8- T lymphocytes from lpr/lpr mice. Mol Cell Biol (1989) 0.90
The histone acetyltransferase domains of CREB-binding protein (CBP) and p300/CBP-associated factor are not necessary for cooperativity with the class II transactivator. J Biol Chem (2001) 0.90
Comparison and quantitation of Ia antigen expression on cultured macroglia and ameboid microglia from Lewis rat cerebral cortex: analyses and implications. J Neuroimmunol (1989) 0.89
A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). Int J Clin Pharmacol Ther Toxicol (1985) 0.89
Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DN alpha/DO beta heterodimer. J Immunol (2000) 0.89